Charlotte, North Carolina 28204

  • Lymphoma


An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas

Study summary:

This is a Phase 1, open-label, multicenter study of HMPL-689 administered orally to patients with relapsed or refractory lymphoma. This study will consist of a dose escalation stage (Stage 1) and a dose expansion stage (Stage 2). Dose Escalation Stage (Stage 1): This stage will end when any of the following criteria is met: - The dose level 1 demonstrates an excessive toxicity, ie, 3 dose limiting toxicities (DLTs) are observed out of the first 3 patients at dose level 1. - The maximum sample size is reached. - The MTD and/or RP2D is confirmed. Dose Expansion Stage (Stage 2): To further characterize the safety and explore the preliminary anti-tumor activity of HMPL-689 at RP2D, patients with B cell lymphoma will be enrolled in the dose expansion stage.


Inclusion Criteria: 1. (ECOG) performance status of 0 or 1; 2. Histologically confirmed lymphoma (tumor types are restricted to CLL, SLL, FL, MZL, LPL/WM, and MCL.) 3. Patients with relapsed or refractory NHL for whom: - Standard of care treatment options no longer exist (Stage 1 only) - Standard of care treatment options no longer exist with the exception of PI3K-delta inhibitors (Stage 2 only) 4. Expected survival of more than 24 weeks Exclusion Criteria: Patients who meet any of the following criteria will be excluded from study entry: 1. Primary central nervous system (CNS) lymphoma; 2. Any of the following laboratory abnormalities Absolute neutrophil count <1.5×10^9/L, Hemoglobin <90 g/L Platelets <100 ×10^9/L 3. Inadequate organ function, defined by the following: - Total bilirubin ≥1.5 times the upper limit of normal (× ULN) - AST or ALT > 2.5 × ULN - Estimated creatinine clearance (CrCl) per Cockcroft-Gault - Dose Escalation stage of trial (Stage 1) - CrCl < 50 mL/min - Dose Expansion stage of trial (Stage 2) - CrCl <30 mL/min 4. Clinically significant history of liver disease, 5. Prior treatment with any PI3Kδ inhibitors 6. Any prior use of the following: cancer therapy within 3 weeks of study treatment, GCSF within 7 days of screening, steroid therapy or targeted anti-neoplastic intent within 7 days of treatment, any use of strong CYP3A4 inducers within 2 weeks prior to initiation of study treatment, prior autologous transplant within 6 months of study treatment, prior allogenic stem cell transplant within 6 months of study treatment, 7. Clinically significant active infection 8. Major surgical procedure within 4 weeks prior to initiation of study treatment; 9. Adverse events from prior anti-neoplastic therapy that have not resolved to Grade less than or equal to 1, except for alopecia; 10. New York Heart Association (NYHA) Class II or greater congestive heart failure 11. Congenital long QT syndrome or QTc >470 msec; 12. Currently use medication known to cause QT prolongation or torsades de pointes 13. History of myocardial infarction or unstable angina within 6 months prior to initiation of study treatment; 14. History of stroke or transient ischemic attack within 6 months prior to initiation of study treatment; 15. Inability to take oral medication, prior surgical procedures affecting absorption, or active peptic ulcer disease; 16. History of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis); 17. History of drug induced pneumonitis



Primary Contact:

Study Director
Vijay Jayaprakash, MD
Hutchison Medipharma Limited

Vijay Jayaprakash, MD
Phone: 9739006617

Backup Contact:

Alisha Khullar, MS
Phone: 9732873081

Location Contact:

Charlotte, North Carolina 28204
United States

Nilanjan Ghosh, MD
Phone: 980-442-4363

Site Status: Recruiting

Data Source:

Date Processed: September 24, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.